LinkedIn
YouTube
Instagram
Contact Us
1-800-850-9132
Log In
#KidneyCancer
@KidneyCancer

YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.

ACCESS INFORMATION & LITERATURE
JOIN NOW
ABOUT DISEASE TREATMENT
GET INFORMATION
SUPPORT RESEARCH
MAKE A DONATION

Upcoming Events

FIND MORE

Publications

NCCN GUIDELINES FOR PATIENTS

Kidney Cancer

DOWNLOAD BOOK
WE HAVE

Kidney Cancer

DOWNLOAD BOOK
VIEW ALL PUBLICATIONS
0
%

5-Year Survival Rate Percentage increase from 2007 through 2013

0

Estimated new cases in the US, this year

0

Estimated Deaths in the US, this year

0

People are living with kidney and renal pelvis cancer, according to NCI SEER data from 2014

Evaluate your treatment options and make decisions

From the Pressroom

News from Kidney Cancer Association This feed has been created by Kidney Cancer Association

More from the Press Room

YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.

DONATE NOW

  Kidney Cancer Association

Kidney Cancer Association

The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers.
Kidney Cancer Association
Kidney Cancer Association3 days ago
In this video, Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of patients with advanced renal cell carcinoma (RCC).
Kidney Cancer Association
Immunotherapy/TKI Combinations in Advanced RCC
Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.
targetedonc.com
16 2    View on Facebook
Kidney Cancer Association
Kidney Cancer Association4 days ago
According to findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany, Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC).
Kidney Cancer Association
Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combo prolongs progression-free survival compared with sunitinib as first-line therapy in patients with advanced RCC
renalandurologynews.com
3    View on Facebook
Kidney Cancer Association
Kidney Cancer Association5 days ago
Join us for our FREE patient and family member meeting at the Cleveland Clinic Taussig Cancer Center Sunday, Nov. 11 from 12 to 3:45 p.m. ET. Lunch will be provided. To register go to: https://secure.kidneycancer.org/np/clients/kca/event.jsp?event=5207
Kidney Cancer Association
4 2    View on Facebook

  #KidneyCancer

  kidneycancerassociation

3 days ago
  • 15
  • 1
4 days ago
  • 11
  • 0
5 days ago
  • 10
  • 0

  Kidney Cancer

Menu